Dex Pharma SLU-PP AMPK Activator 5mg/3mL Pen

• Enhanced Fat Oxidation: Directly triggers the breakdown of fatty acids for energy, making it a powerful tool for body recomposition and stubborn fat loss.
• Mitochondrial Biogenesis: Increases the number and efficiency of mitochondria, leading to better cellular energy production and overall metabolic health.
• Increased Endurance: Improves the oxidative capacity of skeletal muscle, allowing for longer and more intense training sessions with delayed onset of fatigue.
• Improved Insulin Sensitivity: Helps regulate blood glucose levels by enhancing how effectively cells uptake and utilize sugar for fuel.

• May support mitochondrial biogenesis

• May increase fatty acid oxidation

• May promote metabolic flexibility

• May enhance cellular energy production

• May support endurance-related adaptations

• May encourage efficient glucose utilization

• May assist healthy metabolic function

• May support body composition research

• May promote exercise-mimetic cellular pathways

• May support healthy aging and longevity research

For a 5mg/3mL SLU-PP pen, research dosages generally range from 500mcg to 1mg daily.

• Titration: Start at 250mcg–500mcg for the first week to assess tolerance, then move to 1mg daily if you feel good.
• Usage: Inject subcutaneously in the morning while fasted; if the pen is 5mg in 3mL, calculate your clicks or units based on 1.66mg per mL.
• Cycle: Run for 6–8 weeks, then take 4 weeks off to maintain sensitivity.

• What is SLU-PP? A potent ERR agonist and AMPK activator that mimics the metabolic effects of exercise.
• What are the primary benefits? It is designed to accelerate fat loss, improve glucose metabolism, and enhance physical endurance.
• How should it be administered? It is typically administered via subcutaneous injection using the pre-filled pen.
• What is the recommended timing? Most researchers find the best results with once-daily morning administration.
• Should it be taken fasted? Yes, taking it in a fasted state may amplify the AMPK-mediated fat-burning effects.
• Does it require cycling? Standard research cycles often run for 4 to 8 weeks followed by a break.
• Can it be stacked? Yes, it is frequently paired with MOTS-c or GLP-1 agonists for synergistic metabolic results.
• How should the pen be stored? Keep the pen refrigerated (2°C–8°C) to maintain peptide stability.
• What is the shelf life once opened? As long as it's refrigerated and sanitized, it lasts up to 60 days after the first use.
• Are there any common side effects? Some users report mild fatigue or transient changes in appetite as metabolism adjusts.
• Does it replace exercise? No, it works best as an enhancer to a consistent training and nutrition program.
• What is the concentration? This specific pen contains 5mg of SLU-PP in a 3mL solution.
• Is it safe for muscle mass? Studies suggest it helps maintain lean tissue while specifically targeting fat oxidation.
• How often is it used? Common protocols involve daily use or a "5 days on, 2 days off" schedule.

SLU-PP-332 is an investigational exercise-mimetic research compound. It is often discussed online alongside peptides, but technically it is not a peptide; it is a synthetic small-molecule agonist of the estrogen-related receptors, also known as ERRα, ERRβ, and ERRγ. These receptors are involved in mitochondrial function, energy metabolism, fatty-acid oxidation, and some of the cellular adaptations normally associated with exercise.

SLU-PP-332 is currently being researched and is not registered as an approved treatment. Most available evidence is preclinical, mainly from cell and mouse studies. At this stage, there does not appear to be published human clinical trial evidence confirming safety, dosing, or effectiveness in people.

1. Original discovery research — ERR activation and exercise-like gene signalling

A 2023 study published in ACS Chemical Biology identified SLU-PP-332 as a synthetic pan-ERR agonist, meaning it activates all three estrogen-related receptors: ERRα, ERRβ, and ERRγ. The researchers reported that SLU-PP-332 produced an ERRα-dependent transcriptional signature linked to acute aerobic exercise signalling. This is one of the key original papers behind SLU-PP-332 being described as an “exercise mimetic.”

Original article:

https://pubs.acs.org/doi/10.1021/acschembio.2c00720

2. Metabolic syndrome and obesity research — reduced fat mass in mouse models

A 2024 study published in the Journal of Pharmacology and Experimental Therapeutics investigated SLU-PP-332 in mouse models of obesity and metabolic syndrome. The study reported that SLU-PP-332 increased energy expenditure and fatty-acid oxidation, while reducing fat-mass accumulation. The researchers described pharmacological ERR activation as a potential approach for metabolic disease research, but the findings were still preclinical and based on animal models.

Original article:

https://jpet.aspetjournals.org/article/S0022-3565%2824%2917158-3/fulltext

PubMed listing:

https://pubmed.ncbi.nlm.nih.gov/37739806/

Full article on PubMed Central:

https://pmc.ncbi.nlm.nih.gov/articles/PMC10801787/

3. Exercise-mimetic performance research — endurance effects in mice

Research from the University of Florida highlighted SLU-PP-332’s potential as an exercise-mimetic compound in mice. The reported findings suggested that SLU-PP-332 increased energy expenditure, enhanced fat metabolism, and improved exercise endurance in mouse models, without simply making the mice eat less or move more. This supports the idea that the compound may influence internal metabolic pathways rather than acting as a traditional appetite suppressant.

University of Florida summary:

https://news.ufl.edu/2023/09/exercise-mimicking-drug/

MedicalXpress summary:

https://medicalxpress.com/news/2023-09-exercise-mimicking-drug-weight-boosts-muscle.html

4. Heart-failure research — cardiometabolic protection in preclinical models

A study published in Circulation investigated novel pan-ERR agonists, including SLU-PP-332, in the context of heart failure and cardiac metabolism. The research reported cardioprotective effects in experimental models, suggesting that ERR activation may be relevant not only to skeletal muscle and fat metabolism but also to heart-energy pathways. This area remains preclinical and should not be presented as proven heart-treatment evidence in humans.

Original article:

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.066542

5. Newer compound-development research — oral bioavailability challenges

One limitation of SLU-PP-332 is that it has poor oral bioavailability, meaning it is not well suited as an oral drug in its original form. A later research paper discussed the development of related orally active ERR agonists, including SLU-PP-915, building on SLU-PP-332’s exercise-mimetic mechanism. This shows that SLU-PP-332 is an important research tool, but newer related compounds are being explored to overcome practical drug-development limitations.

PubMed listing:

https://pubmed.ncbi.nlm.nih.gov/41421047/

ScienceDirect article:

https://www.sciencedirect.com/science/article/abs/pii/S0022356525403000

6. Metabolism and detection research — doping-control interest

More recent analytical research has examined the metabolism and detection of SLU-PP-332 and related ERR agonists. These studies are relevant because exercise-mimetic compounds may have potential misuse in sports or performance enhancement. The research focuses on analytical characterisation and possible metabolites, rather than proving human benefits or safe usage.

PubMed listing:

https://pubmed.ncbi.nlm.nih.gov/41688415/

Wiley article:

https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.70035

Related analytical article:

https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/rcm.70039

7. Human evidence status — no confirmed human clinical-use data yet

As of the current published literature, SLU-PP-332 appears to remain at the preclinical research stage, with evidence mainly from cell and animal studies. A 2025 review specifically notes the absence of human data, meaning there are no established human dosing protocols, long-term safety data, or approved clinical indications. For product wording, it is important to avoid making direct claims that SLU-PP-332 causes weight loss, improves fitness, treats disease, or replaces exercise in humans.

Review article:

https://ujpronline.com/index.php/journal/article/view/1355/1932

Quick Research Summary

SLU-PP-332 is being researched as an exercise-mimetic ERR agonist that may influence mitochondrial activity, energy expenditure, fatty-acid oxidation, endurance pathways, and metabolic regulation. Early studies in cells and mice have shown promising effects on exercise-like gene signalling, fat metabolism, endurance capacity, and metabolic-syndrome markers. However, the research is still largely preclinical

Exercise mimetic research and metabolic effects:

https://pmc.ncbi.nlm.nih.gov/articles/PMC10801787/

Washington University research on exercise-mimetic compounds:

https://www.eurekalert.org/news-releases/1037097

2025 review of SLU-PP-332 and ERR agonists:

https://ujpronline.com/index.php/journal/article/download/1355/1899

Overview of SLU-PP-332 metabolic and endurance research:

https://rjstonline.com/HTML_Papers/Research%20Journal%20of%20Science%20and%20Technology__PID__2024-16-4-9.html